Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · UnitedHealth (UNH)

UnitedHealth adds Scott Gottlieb, former FDA commissioner, as independent director

Neutral Impact 2 of 5 leadership Written later

UnitedHealth Group named Scott Gottlieb, M.D., a former FDA commissioner, as an independent director effective immediately, as announced November 18, 2025. He has not yet been assigned to any board committees. The filing describes standard director compensation and indemnification arrangements, and no financial results or guidance were reported.

Key points

  • Scott Gottlieb, M.D. appointed independent director, effective immediately, announced November 18, 2025
  • Gottlieb has not yet been appointed to any board committees
  • He served as FDA commissioner from 2017 to 2019 and also serves as a director of Pfizer, Tempus AI and Illumina
  • Compensation follows the company's standard non-employee director program; he is entering the standard indemnification agreement

The filing

CompanyUnitedHealth (UNH)
Form8-K, current report
Filed with the SECNov 21, 2025, 5:20 PM ET
Accession number0000731766-25-000314

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.